We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ULURU Inc (GM) | USOTC:ULUR | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.000001 | 0.000001 | 0.00 | 01:00:00 |
Nevada
|
41-2118656
|
(State or Other Jurisdiction of
|
(I.R.S. Employer Identification No.)
|
Incorporation or Organization)
|
4452 Beltway Drive
Addison, Texas
|
75001
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer
|
o
|
Accelerated filer
|
o
|
|||
Non-accelerated filer
|
o
|
Smaller reporting company
|
þ
|
|||
Emerging growth company
|
o
|
ITEM 1.
|
Fin
an
cial Statements.
|
March 31, 2017
|
December 31, 2016
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
ASSETS
|
||||||||
Current Assets
|
||||||||
Cash and cash equivalents
|
$ | 5,634,481 | $ | 36,615 | ||||
Accounts receivable, net
|
2,941 | 61,788 | ||||||
Accounts receivable – related party, net
|
129,701 | --- | ||||||
Inventory
|
526,308 | 559,600 | ||||||
Prepaid expenses and deferred charges
|
71,667 | 135,394 | ||||||
Total Current Assets
|
6,365,098 | 793,397 | ||||||
Property, Equipment and Leasehold Improvements, net
|
94,025 | 126,741 | ||||||
Other Assets
|
||||||||
Intangible asset - patents, net
|
207,647 | 216,781 | ||||||
Intangible asset - licensing rights, net
|
3,970,289 | 3,181,087 | ||||||
Deposits
|
18,069 | 18,069 | ||||||
Total Other Assets
|
4,196,005 | 3,415,937 | ||||||
TOTAL ASSETS
|
$ | 10,655,128 | $ | 4,336,075 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current Liabilities
|
||||||||
Accounts payable
|
$ | 2,038,453 | $ | 2,026,671 | ||||
Accrued liabilities
|
366,616 | 315,300 | ||||||
Accrued interest
|
5,479 | 53 | ||||||
Promissory note payable, current portion
|
--- | 20,000 | ||||||
Deferred revenue, current portion
|
5,764 | 45,764 | ||||||
Total Current Liabilities
|
2,416,312 | 2,407,788 | ||||||
Long Term Liabilities
|
||||||||
Convertible notes payable, net of unamortized debt discount and debt issuance costs
|
302,166 | --- | ||||||
Deferred revenue, net of current portion
|
357,040 | 358,462 | ||||||
Total Long Term Liabilities
|
659,206 | 358,462 | ||||||
TOTAL LIABILITIES
|
3,075,518 | 2,766,250 | ||||||
COMMITMENTS AND CONTINGENCIES
|
--- | --- | ||||||
STOCKHOLDERS' EQUITY
|
||||||||
Preferred Stock - $0.001 par value; 20,000 shares authorized;
|
||||||||
Preferred Stock Series A, 1,000 shares designated; no shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
|
--- | --- | ||||||
Preferred Stock Series B, 1,250 shares designated; 1,250 and nil shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
|
1 | --- | ||||||
Common Stock - $0.001 par value; 200,000,000 shares authorized;
|
||||||||
76,349,431 and 62,974,431 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
|
76,349 | 62,974 | ||||||
Additional paid-in capital
|
68,679,999 | 62,220,850 | ||||||
Accumulated (deficit)
|
(61,176,739 | ) | (60,713,999 | ) | ||||
TOTAL STOCKHOLDERS’ EQUITY
|
7,579,610 | 1,569,825 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$ | 10,655,128 | $ | 4,336,075 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
|
Three Months Ended March 31,
|
||||||||
2017
|
2016
|
|||||||
Revenues
|
||||||||
License fees
|
$ | 1,422 | $ | 101,276 | ||||
Product sales, net
|
215,695 | 7,516 | ||||||
Total Revenues
|
217,117 | 108,792 | ||||||
Costs and Expenses
|
||||||||
Cost of goods sold
|
81,934 | 924 | ||||||
Research and development
|
60,129 | 136,159 | ||||||
Selling, general and administrative
|
394,606 | 318,801 | ||||||
Amortization of intangible assets
|
89,307 | 198,636 | ||||||
Depreciation
|
32,716 | 33,165 | ||||||
Total Costs and Expenses
|
658,692 | 687,685 | ||||||
Operating (Loss)
|
(441,575 | ) | (578,893 | ) | ||||
Other Income (Expense)
|
||||||||
Interest and miscellaneous income
|
2 | 22 | ||||||
Interest expense
|
(21,277 | ) | (46,758 | ) | ||||
Foreign currency transaction gain
|
110 | 4,286 | ||||||
Accommodation fee due on promissory note
|
--- | (25,000 | ) | |||||
(Loss) Before Income Taxes
|
(462,740 | ) | (646,343 | ) | ||||
Income taxes
|
--- | --- | ||||||
Net (Loss)
|
$ | (462,740 | ) | $ | (646,343 | ) | ||
Basic and diluted net (loss) per common share
|
$ | (0.01 | ) | $ | (0.02 | ) | ||
Weighted average number of common shares outstanding
|
63,123,042 | 37,658,932 | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
|
Three Months Ended March 31,
|
||||||||
2017
|
2016
|
|||||||
OPERATING ACTIVITIES :
|
||||||||
Net loss
|
$ | (462,740 | ) | $ | (646,343 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Amortization of intangible assets
|
89,307 | 198,636 | ||||||
Depreciation
|
32,716 | 33,165 | ||||||
Share-based compensation for stock and options issued to employees
|
4,324 | 11,854 | ||||||
Share-based compensation for options issued to non-employees
|
--- | 16,013 | ||||||
Amortization of debt discount on promissory note
|
--- | 13,015 | ||||||
Amortization of deferred financing costs
|
--- | 9,368 | ||||||
Change in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(70,854 | ) | 262 | |||||
Inventory
|
33,292 | (5,943 | ) | |||||
Prepaid expenses and deferred charges
|
63,727 | 16,091 | ||||||
Accounts payable
|
11,782 | 143,948 | ||||||
Accrued liabilities
|
51,316 | 57,414 | ||||||
Accrued interest
|
5,426 | 2,239 | ||||||
Deferred revenue
|
(41,422 | ) | (101,276 | ) | ||||
Total
|
179,614 | 394,786 | ||||||
Net Cash Used in Operating Activities
|
(283,126 | ) | (251,557 | ) | ||||
INVESTING ACTIVITIES :
|
||||||||
Net Cash Used in Investing Activities
|
--- | --- | ||||||
FINANCING ACTIVITIES :
|
||||||||
Proceeds from issuance of convertible notes and warrant, net
|
983,466 | --- | ||||||
Proceeds from sale of preferred stock, net
|
4,917,526 | --- | ||||||
Proceeds from sale of common stock and warrants, net
|
--- | 1,398,426 | ||||||
Offering costs associated with acquisition of licensing rights in 2015
|
--- | (14,178 | ) | |||||
Additional principle due on promissory note due to accommodation fee
|
--- | 25,000 | ||||||
Proceeds from issuance of promissory notes
|
120,000 | --- | ||||||
Repayment of principle due on promissory notes
|
(140,000 | ) | (135,000 | ) | ||||
Net Cash Provided by Financing Activities
|
5,880,992 | 1,274,248 | ||||||
Net Increase in Cash
|
5,597,866 | 1,022,691 | ||||||
Cash, beginning of period
|
36,615 | 180,000 | ||||||
Cash, end of period
|
$ | 5,634,481 | $ | 1,202,691 | ||||
SUPPLEMENTAL CASH FLOW DISCLOSURE:
|
||||||||
Cash paid for interest
|
$ | 2,420 | $ | 7,577 | ||||
Non-cash investing and financing activities:
|
||||||||
Issuance of common stock for acquisition of licensing rights
|
$ | 869,375 | --- | |||||
Issuance of common stock for principle due on promissory note
|
--- | $ | 45,000 | |||||
Issuance of common stock for interest due on promissory note
|
--- | $ | 2,239 | |||||
Issuance of common stock for services
|
--- | $ | 36,000 | |||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
|
NOTE 1.
|
COMPANY OVERVIEW AND BASIS OF PRESENTATION
|
NOTE 2.
|
SIGNIFICANT ACCOUNTING POLICIES
|
NOTE 3.
|
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS
|
NOTE 4.
|
SEGMENT INFORMATION
|
Revenues
|
2017
|
%
|
2016
|
%
|
||||||||||||
Domestic
|
$ | 2,537 | 1 | % | $ | 7,516 | 7 | % | ||||||||
International
|
214,580 | 99 | % | 101,276 | 93 | % | ||||||||||
Total
|
$ | 217,117 | 100 | % | $ | 108,792 | 100 | % |
NOTE 5.
|
INVENTORY
|
Inventory
|
March 31, 2017
|
December 31, 2016
|
||||||
Raw materials
|
$ | 35,059 | $ | 35,800 | ||||
Work-in-progress
|
384,084 | 424,741 | ||||||
Finished goods
|
107,165 | 99,059 | ||||||
Total
|
$ | 526,308 | $ | 559,600 |
NOTE 6.
|
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS
|
Property, equipment and leasehold improvements
|
March 31, 2017
|
December 31, 2016
|
||||||
Laboratory equipment
|
$ | 424,888 | $ | 424,888 | ||||
Manufacturing equipment
|
1,604,894 | 1,604,894 | ||||||
Computers, office equipment, and furniture
|
151,280 | 151,280 | ||||||
Computer software
|
4,108 | 4,108 | ||||||
Leasehold improvements
|
95,841 | 95,841 | ||||||
2,281,011 | 2,281,011 | |||||||
Less: accumulated depreciation and amortization
|
(2,186,986 | ) | (2,154,270 | ) | ||||
Property, equipment and leasehold improvements, net
|
$ | 94,025 | $ | 126,741 |
NOTE 7.
|
INTANGIBLE ASSETS
|
Intangible assets – patents
|
March 31, 2017
|
December 31, 2016
|
||||||
Patent - Amlexanox (Aphthasol®)
|
$ | 2,090,000 | $ | 2,090,000 | ||||
Patent - Amlexanox (OraDisc™ A)
|
6,873,080 | 6,873,080 | ||||||
Patent - OraDisc™
|
73,000 | 73,000 | ||||||
Patent - Hydrogel nanoparticle aggregate
|
589,858 | 589,858 | ||||||
9,625,938 | 9,625,938 | |||||||
Less: accumulated amortization
|
(7,390,981 | ) | (7,381,847 | ) | ||||
Less: reserve for impairment
|
(2,027,310 | ) | (2,027,310 | ) | ||||
Intangible assets - patents, net
|
$ | 207,647 | $ | 216,781 |
Calendar Years
|
Future Amortization
Expense
|
|||
2017 (Nine months)
|
$ | 27,910 | ||
2018
|
37,044 | |||
2019
|
37,044 | |||
2020
|
37,145 | |||
2021
|
37,044 | |||
2022 & Beyond
|
31,460 | |||
Total
|
$ | 207,647 |
Intangible assets - licensing rights
|
March 31, 2017
|
December 31, 2016
|
||||||
Intangible assets – licensing rights, gross
|
$ | 4,381,881 | $ | 3,512,506 | ||||
Less: accumulated amortization
|
(411,592 | ) | (331,419 | ) | ||||
Intangible assets - licensing rights, net
|
$ | 3,970,289 | $ | 3,181,087 |
Calendar Years
|
Future Amortization
Expense
|
|||
2017 (Nine months)
|
$ | 313,653 | ||
2018
|
416,303 | |||
2019
|
416,303 | |||
2020
|
416,303 | |||
2021
|
416,303 | |||
2022 & Beyond
|
1,991,424 | |||
Total
|
$ | 3,970,289 |
NOTE 8.
|
ACCRUED LIABILITIES
|
Accrued Liabilities
|
March 31, 2017
|
December 31, 2016
|
||||||
Accrued compensation/benefits
|
$ | 310,027 | $ | 274,874 | ||||
Accrued insurance payable
|
23,485 | 40,422 | ||||||
Accrued property taxes
|
1,350 | --- | ||||||
Accrued royalties
|
31,754 | --- | ||||||
Product rebates/returns
|
--- | 4 | ||||||
Total accrued liabilities
|
$ | 366,616 | $ | 315,300 |
NOTE 9.
|
PROMISSORY NOTES PAYABLE
|
NOTE 10.
|
CONVERTIBLE DEBT
|
As of March 31, 2017
|
|||||||||||||||||||||||||||||
Transaction
|
Initial
Principal
Amount
|
Interest
Rate
|
Maturity
Date
|
Conversion Price
|
Principal
Balance
|
Unamortized
Debt
Discount
|
Unamortized Debt Issuance Costs
|
Carrying
Value
|
|||||||||||||||||||||
February 2017 Note
|
$ | 500,000 | 12.5 | % |
02/27/2019
|
$ | 0.04 | $ | 500,000 | $ | 340,650 | $ | 8,267 | $ | 151,083 | ||||||||||||||
March
2017 Note
|
$ | 500,000 | 12.5 | % |
03/31/2019
|
$ | 0.04 | $ | 500,000 | $ | 340,650 | $ | 8,267 | $ | 151,083 | ||||||||||||||
Total
|
$ | 1,000,000 | $ | 1,000,000 | $ | 681,300 | $ | 16,534 | $ | 302,166 |
NOTE 11.
|
EQUITY TRANSACTIONS
|
NOTE 12.
|
STOCKHOLDERS’ EQUITY
|
Number of Shares of Common Stock Subject to Exercise
|
Weighted – Average
Exercise Price
|
|||||||
Balance as of December 31, 2016
|
26,179,560 | $ | 0.11 | |||||
Warrants issued
|
57,055,057 | $ | 0.04 | |||||
Warrants exercised
|
--- | --- | ||||||
Warrants cancelled
|
--- | --- | ||||||
Balance as of March 31, 2017
|
83,234,617 | $ | 0.06 |
Date of Expiration
|
Number of Warrant Shares of Common Stock Subject to Expiration
|
|||
March 14, 2018
|
660,000 | |||
January 15, 2019
|
80,000 | |||
April 30, 2020
|
194,118 | |||
March 30, 2021
|
25,245,442 | |||
March 31, 2027
|
57,055,057 | |||
Total
|
83,234,617 |
NOTE 13.
|
EARNINGS PER SHARE
|
March 31, 2017
|
December 31, 2016
|
|||||||
Warrants to purchase Common Stock
|
83,234,617 | 26,179,560 | ||||||
Stock options to purchase Common Stock
|
578,403 | 691,237 | ||||||
Common stock issuable upon the assumed conversion of our convertible promissory notes (1)
|
31,250,000 | --- | ||||||
Common stock issuable upon the assumed conversion of our Series B preferred stock (2)
|
125,000,000 | --- | ||||||
Total
|
240,063,020 | 26,870,797 |
(1)
|
As part of the February 2017 Note and the March 2017 Note, at the holder’s option, all unpaid principle and interest due under each convertible promissory note may be converted into shares of Common Stock based on a conversion price of $0.04 per share. The February 2017 Note and the March 2017 Note matures on February 27, 2019 and March 31, 2019, respectively, and on each maturity date each convertible promissory note, and accrued interest thereon, is subject to mandatory conversion based on a conversion price of $0.04 per share. For the purposes of this Table, we have assumed that all outstanding principal and interest will be converted on each applicable maturity date.
|
(2)
|
Pursuant to the March 2017 Offering, Velo LLC purchased 1,250 shares of Series B Convertible Preferred Stock of the Company for $5,000,000. The Series B Convertible Preferred Stock that was issued in the March 2017 Offering, (a) votes together with the Common Stock as a single class (subject to standard protective provisions for the Series B Convertible Preferred Stock), (b) has the same dividend rights as the Common Stock, (c) has a liquidation preference equal to the greater of its purchase price and its as converted-to-Common Stock value, (d) automatically converts into Common Stock if the number of authorized shares of Common Stock is increased within 190 days of the second closing as necessary to permit all outstanding convertible or exercisable securities (including the Series B Convertible Preferred Stock) to convert to Common Stock, and (e) is convertible into Common Stock at the discretion of the holder, subject to the availability of authorized shares, at an as-converted-to-Common Stock purchase price of $0.04 per share.
|
NOTE 14.
|
SHARE BASED COMPENSATION
|
Three Months Ended
March 31,
|
||||||||
2017
|
2016
|
|||||||
Research and development
|
$ | 1,663 | $ | 8,670 | ||||
Selling, general and administrative
|
2,661 | 19,197 | ||||||
Total share-based compensation expense
|
$ | 4,324 | $ | 27,867 |
Stock Options
|
Weighted Average Exercise Price per Share
|
|||||||
Outstanding as of December 31, 2016
|
691,237 | $ | 1.94 | |||||
Granted
|
--- | --- | ||||||
Forfeited/cancelled
|
(112,834 | ) | $ | 2.13 | ||||
Exercised
|
--- | --- | ||||||
Outstanding as of March 31, 2017
|
578,403 | $ | 1.91 |
Options Outstanding
|
Options Exercisable
|
|||||||||||||||||
Stock Options Outstanding
|
Weighted Average Exercise Price per Share
|
Weighted Average Remaining Contractual Life in Years
|
Stock Options Exercisable
|
Weighted Average Exercise Price per Share
|
||||||||||||||
340,000 | $ | 0.33 | 6.0 | 340,000 | $ | 0.33 | ||||||||||||
215,000 | 1.15 | 7.5 | 215,000 | 1.15 | ||||||||||||||
23,403 | 31.75 | 1.0 | 23,403 | 31.75 | ||||||||||||||
578,403 | $ | 1.91 | 6.3 | 578,403 | $ | 1.91 |
NOTE 15.
|
FAIR VALUE MEASUREMENTS
|
Level 1
|
—
|
Valuations based on quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
Level 2
|
—
|
Valuations based on observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable or can be corroborated by observable market data.
|
Level 3
|
—
|
Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.
|
Description
|
March 31, 2017
|
December 31, 2016
|
||||||
Liabilities:
|
||||||||
Convertible promissory note – March 2017
|
$ | 500,000 | --- | |||||
Convertible promissory note – February 2017
|
$ | 500,000 | --- | |||||
Promissory note – December 2016
|
--- | $ | 20,000 | |||||
Total
|
$ | 1,000,000 | $ | 20,000 |
NOTE 16.
|
INCOME TAXES
|
NOTE 17.
|
COMMITMENTS AND CONTINGENCIES
|
Calendar Years
|
Future Lease Expense
|
|||
2017 (Nine months)
|
$ | 90,031 | ||
2018
|
28,908 | |||
2019
|
--- | |||
2020
|
--- | |||
Total
|
$ | 118,939 |
Name
|
2017
|
2016
|
2015
|
2014 – 2011 |
Total
|
|||||||||||||||
Kerry P. Gray (1) (2) (3) (4)
|
$ | --- | $ | --- | $ | 275,153 | $ | 150,000 | $ | 425,153 | ||||||||||
Terrance K. Wallberg
|
23,334 | (5,207 | ) | 53,540 | --- | 71,667 | ||||||||||||||
Other employees
|
--- | (54,871 | ) | 54,871 | --- | --- | ||||||||||||||
Total
|
$ | 23,334 | $ | (60,078 | ) | $ | 383,564 | $ | 150,000 | $ | 496,820 |
(1)
|
On November 19, 2015, Mr. Gray resigned as the Company’s President and Chief Executive Officer and on February 18, 2016 resigned as a director for the Company.
|
(2)
|
The Company is asserting in a dispute with Mr. Gray that certain amounts recorded as being owed to Mr. Gray are not in fact owed to Mr. Gray or are offset by amounts Mr. Gray owes to the Company.
|
(3)
|
During 2015, Mr. Gray temporarily deferred compensation of $275,153 which consisted of $51,770 earned as salary compensation for his duties as President of the Company, $186,083 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors, and $37,300 as a temporary advance of working capital.
|
(4)
|
During 2014, Mr. Gray temporarily deferred compensation of $150,000 which consisted of $62,500 earned as salary compensation for his duties as President of the Company and $87,500 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2014, Mr. Gray was also repaid $269,986 of temporarily deferred compensation, of which $100,000 was used by Mr. Gray for funding required pursuant to a Securities Purchase Agreement, dated March 14, 2013 (the “March 2013 Offering”). Prior to 2014, over a three year period Mr. Gray temporarily deferred, at various times, aggregate compensation of $582,486 and during the same time period was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
|
NOTE 18.
|
LEGAL PROCEEDINGS
|
NOTE 19.
|
SUBSEQUENT EVENTS
|
ITEM 2.
|
Man
age
ment’s Discussion and Analysis of Financial Condition and Results of Operations.
|
Three Months Ended March 31,
|
||||||||
Technology
|
2017
|
2016
|
||||||
Wound care & nanoparticle
|
$ | 4,000 | $ | 13,000 | ||||
OraDisc™
|
5,000 | 4,000 | ||||||
Aphthasol® & other technologies
|
--- | --- | ||||||
Total
|
$ | 9,000 | $ | 17,000 |
Consolidated Cash Flow Data
|
||||||||
Three Months Ended March 31,
|
||||||||
Net Cash Provided by (Used in)
|
2017
|
2016
|
||||||
Operating activities
|
$ | (283,000 | ) | $ | (251,000 | ) | ||
Investing activities
|
--- | --- | ||||||
Financing activities
|
5,881,000 | 1,274,000 | ||||||
Net increase in cash and cash equivalents
|
$ | 5,598,000 | $ | 1,023,000 |
§
|
our ability to successfully commercialize our wound management products and the market acceptance of these products;
|
§
|
our ability to establish and maintain collaborative arrangements with business partners for the development and commercialization of certain product opportunities;
|
§
|
scientific progress in our development programs;
|
§
|
the marketing and sales efforts of our distributors and sub-distributors;
|
§
|
the costs involved in filing, prosecuting and enforcing patent claims and our maintenance of patent rights;
|
§
|
competing product developments;
|
§
|
the trading volume and price of our capital stock;
|
§
|
the actions of parties whose consents, waivers or prompt responses are required for approval of a financing (such as parties with rights of first refusal or consent rights);
|
§
|
our general financial situation, including our revenues, liquidity, capitalization and other factors; and
|
§
|
the cost of manufacturing and production scale-up.
|
Payments Due By Period
|
||||||||||||||||||||
Contractual Cash Obligations
|
Total
|
Less Than
1 Year
|
1-2
Years
|
3-5
Years
|
After 5
Years
|
|||||||||||||||
Operating leases
|
$ | 118,939 | $ | 118,939 | $ | --- | $ | --- | $ | --- | ||||||||||
Total contractual cash obligations
|
$ | 118,939 | $ | 118,939 | $ | --- | $ | --- | $ | --- |
ITEM 3.
|
Qua
ntita
tive and Qualitative Disclosures About Market Risk.
|
ITEM 4.
|
Co
ntr
ols and Procedures.
|
ITEM 1.
|
L
ega
l Proceedings.
|
ITEM 1A.
|
R
is
k Factors.
|
ITEM 2.
|
Unr
egis
tered Sales of Equity Securities and Use of Proceeds.
|
ITEM 3.
|
D
efau
lts Upon Senior Securities.
|
ITEM 4.
|
M
in
e Safety Disclosures.
|
ITEM 5.
|
O
th
er Information.
|
ULURU Inc.
|
||||
Date: May 15, 2017
|
By:
|
/s/ Vaidehi Shah
|
||
Vaidehi Shah
|
||||
Chief Executive Officer
|
||||
(Principal Executive Officer)
|
||||
Date: May 15, 2017
|
By:
|
/s/ Terrance K. Wallberg
|
||
Terrance K. Wallberg
|
||||
Chief Financial Officer and Vice President
|
||||
(Principal Financial and Accounting Officer)
|
1 Year ULURU (GM) Chart |
1 Month ULURU (GM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions